News

Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today?

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Eli Lilly: 50% Upside For LLY Stock?

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Lilly pill cuts body weight by 12.4% in trial, lagging Novo's Wegovy injection

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight in a late-stage ...

Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried?

The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...

Eli Lilly Shares Plummet 14% Toward Worst Day In 25 Years—Here’s Why It’s Down

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

S&P 500 eases with Eli Lilly; Nasdaq manages record closing high

The Dow and S&P 500 eased on Thursday, as shares of Eli Lilly dropped after data from its oral weight loss drug disappointed, ...

Does This $856 Million Investment Make Eli Lilly Stock a Buy?

In May, it announced it would acquire SiteOne Therapeutics, a drugmaker with a promising investigational medicine for pain.
Benzinga.com14h

Eli Lilly's Orforglipron Data Is Not Disastrous: Analyst

Orforglipron cut weight by 12.4% vs. 0.9% with placebo, below 15% expectations. BofA lowered Eli Lilly's price forecast to ...